In a remarkable leap forward for genetic medicine, researchers at Oregon State University have cracked one of the most formidable challenges in gene therapy delivery: ensuring that therapeutic genes and gene-editing tools not only enter cells but reach the precise intracellular compartments where they can be effective. Published in the prestigious journal Nature Biotechnology, this breakthrough promises to enhance the efficacy and safety of next-generation genetic treatments.
Gene therapies hold tremendous promise for treating a myriad of diseases by introducing or editing genetic material inside a patient’s cells. However, a perennial obstacle has been that once these therapies penetrate a cell’s outer membrane, the genetic cargo tends to be routed to lysosomes. These lysosomes act as the cell’s degradation centers, where the therapeutic material is effectively destroyed before it can exert its intended effect. Overcoming this biological disposal system to enable the therapeutic payload’s escape into the correct subcellular environment has remained a critical bottleneck.
Under the leadership of graduate student Antony Jozić, the Oregon State research team employed a novel DNA-based barcoding assay to track the fate of genetic cargo delivered by lipid nanoparticles (LNPs) in living mouse models. This pioneering technique allows for real-time quantification of how many nanoparticles successfully bypass lysosomal degradation versus those lost to cellular recycling pathways. The capacity to measure this phenomenon with unprecedented accuracy provides a powerful platform to rationally design more efficient gene delivery vehicles.
Ionizable lipids, specialized lipid molecules whose charge changes according to local acidity, serve as core components of lipid nanoparticles and play a crucial role in cargo packaging and cellular membrane interaction. By harnessing the insights generated from their in vivo barcoding system, the researchers created optimized ionizable lipid formulations that markedly improve the delivery efficiency of genetic therapies. These breakthroughs enable potent gene editing at significantly lower dosages than previously possible, minimizing potential side effects and off-target effects.
Professor Gaurav Sahay, who mentored Jozić and spearheaded the project, emphasized the transformative nature of their approach. “Our ability to precisely measure the intracellular trafficking of therapeutic genes shifts the paradigm,” said Sahay. “With these detailed insights, we can design LNPs that not only penetrate cells but strategically avoid lysosomal degradation, unlocking much higher efficacy in gene delivery.”
Collaborations spanning institutions worldwide—including Oregon Health & Science University, Tennessee Technological University, Yeungnam University in South Korea, and the University of Brest in France—contributed to the study’s multinational and multidisciplinary expertise. Notably, collaboration with Paul-Alain Jaffrès and his student Chole Le Roux in France was instrumental in engineering some of the most advanced ionizable lipids documented to date, which exhibited dramatically improved gene-editing delivery performance.
The implications of this work extend beyond enhanced delivery. By solving the longstanding challenge of quantifying and controlling endosomal escape—the process by which therapeutic cargo exits intracellular vesicles—this research offers a roadmap for developing safer and more effective RNA and gene-editing medicines. Such medicines could potentially transform treatment paradigms for genetic disorders, cancers, and a host of other diseases with underlying genetic etiologies.
Subcellular trafficking of nanoparticles has been notoriously difficult to study in vivo due to the complexity and dynamic nature of living tissues. The DNA barcoding assay developed in this study is revolutionary because it provides a quantitative and scalable method to dissect this intricate process within a living organism, rather than relying solely on in vitro assays that may not accurately reflect physiological conditions.
This technical advancement also addresses a central limitation of current gene therapy delivery: the requirement for high-dose administrations to overcome the inefficiency of delivery systems. By enabling efficient delivery at substantially reduced doses, the improved LNP designs pave the way for reducing immunogenic responses and toxicity associated with repeated or high-dose treatments, thereby broadening the therapeutic window.
Supporting agencies such as the National Institutes of Health, Defense Advanced Research Projects Agency (DARPA), and the M.J. Murdock Charitable Trust recognized the potential impact of this research and provided vital funding. The combination of innovative science, cutting-edge technology, and international collaboration exemplifies the synergy necessary for breakthroughs in complex biomedical challenges.
This study highlights the role of Oregon State University as a rising leader in drug delivery sciences and biotechnology innovation. The strong mentorship environment and emphasis on collaborative research foster conditions where graduate students like Antony Jozić can make pivotal contributions that push the frontiers of medicine.
Looking forward, the lessons learned from mapping intracellular pathways of gene therapy payloads may be extended to deliver a range of therapeutic cargos, including mRNA vaccines, siRNA, and CRISPR-based gene editing tools. Ultimately, this line of research holds the promise to make gene therapy more precise, scalable, and accessible for a wide spectrum of patients worldwide.
The work published on March 11, 2026, serves as a beacon for overcoming one of gene therapy’s most intractable problems—achieving reliable, efficient, and safe delivery deep within cells—and represents a major step toward realizing the full potential of genetic medicines.
Subject of Research: Animals
Article Title: In vivo endosomal escape assay reveals mechanisms for efficient hepatic LNP delivery
News Publication Date: 11-Mar-2026
Web References:
http://dx.doi.org/10.1038/s41587-026-03022-6
Keywords
Gene Therapy, Lipid Nanoparticles, Endosomal Escape, Ionizable Lipids, Genetic Medicine, Gene Editing, Therapeutic Delivery, LNP Design, Intracellular Trafficking, RNA Therapeutics, Nanomedicine, In Vivo Assay
Tags: DNA barcoding assay in gene therapygene therapy delivery challengesgene therapy safety advancementsimproving gene editing efficacyintracellular gene therapy targetinglipid nanoparticle gene carriersmouse models in genetic medicinenext-generation gene-based treatmentsOregon State University genetic researchovercoming lysosomal degradation in cellsreal-time tracking of gene therapytherapeutic gene intracellular trafficking
